Farallon Capital Management LLC Takes $31.43 Million Position in Assembly Biosciences, Inc. $ASMB

Farallon Capital Management LLC acquired a new position in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,227,590 shares of the biopharmaceutical company’s stock, valued at approximately $31,426,000. Farallon Capital Management LLC owned 16.00% of Assembly Biosciences as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Bank of America Corp DE grew its position in shares of Assembly Biosciences by 6,382.7% during the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 3,319 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in Assembly Biosciences in the 3rd quarter valued at about $485,000. Acadian Asset Management LLC boosted its stake in Assembly Biosciences by 42.1% during the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 6,823 shares during the period. Ellsworth Advisors LLC acquired a new position in Assembly Biosciences during the 3rd quarter valued at about $852,000. Finally, Palumbo Wealth Management LLC grew its position in Assembly Biosciences by 86.4% in the 3rd quarter. Palumbo Wealth Management LLC now owns 34,798 shares of the biopharmaceutical company’s stock worth $891,000 after purchasing an additional 16,131 shares during the last quarter. Institutional investors own 19.92% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ASMB shares. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Assembly Biosciences in a research note on Monday, December 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, January 21st. Finally, Mizuho set a $40.00 target price on Assembly Biosciences and gave the company an “outperform” rating in a research report on Thursday, November 20th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Assembly Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.75.

Assembly Biosciences Price Performance

Shares of NASDAQ:ASMB opened at $28.11 on Monday. Assembly Biosciences, Inc. has a 12 month low of $7.75 and a 12 month high of $39.71. The stock has a market cap of $444.70 million, a price-to-earnings ratio of -5.87 and a beta of 1.11. The stock’s 50 day moving average price is $28.50 and its 200 day moving average price is $29.53.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.